Literature DB >> 32474410

Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden.

Jordan E Axelrad1, Ola Olén2,3,4, Michael C Sachs2, Rune Erichsen5,6, Lars Pedersen5, Jonas Halfvarson7, Johan Askling2, Anders Ekbom2, Henrik Toft Sørensen5, Jonas F Ludvigsson8,9,10,11.   

Abstract

OBJECTIVE: Crohn's disease (CD) is associated with increased risk of small bowel cancer (SBC), but previous studies have been small. We aimed to examine the risk of incident SBC and death from SBC in patients with inflammatory bowel disease (IBD).
DESIGN: In a binational, population-based cohort study from Sweden and Denmark of patients with IBD during 1969-2017 and matched reference individuals from the general population, we evaluated the risk of incident SBC and death from SBC. Cox regression was used to estimate adjusted hazard ratios (aHRs).
RESULTS: We identified 161 896 individuals with IBD (CD: 47 370; UC: 97 515; unclassified IBD: 17 011). During follow-up, 237 cases of SBC were diagnosed in patients with IBD (CD: 24.4/100 000 person-years; UC: 5.88/100 000 person-years), compared with 640 cases in reference individuals (2.81/100 000 person-years and 3.32/100 000 person-years, respectively). This corresponded to one extra case of SBC in 385 patients with CD and one extra case in 500 patients with UC, followed up for 10 years. The aHR for incident SBC was 9.09 (95% CI 7.34 to 11.3) in CD and 1.85 (95% CI 1.43 to 2.39) in UC. Excluding the first year after an IBD diagnosis, the aHRs for incident SBC decreased to 4.96 in CD and 1.69 in UC. Among patients with CD, HRs were independently highest for recently diagnosed, childhood-onset, ileal and stricturing CD. The relative hazard of SBC-related death was increased in both patients with CD (aHR 6.59, 95% CI 4.74 to 9.15) and patients with UC (aHR 1.57; 95% CI 1.07 to 2.32).
CONCLUSION: SBC and death from SBC were more common in patients with IBD, particularly among patients with CD, although absolute risks were low. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Crohn's disease; adenocarcinoma; cancer; inflammatory bowel disease; ulcerative colitis

Year:  2020        PMID: 32474410     DOI: 10.1136/gutjnl-2020-320945

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  4 in total

1.  Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes.

Authors:  Yip Han Chin; Sneha Rajiv Jain; Ming Hui Lee; Cheng Han Ng; Snow Yunni Lin; Aaron Shengting Mai; Mark Dhinesh Muthiah; Fung Joon Foo; Raghav Sundar; David Eng Hui Ong; Wei Qiang Leow; Rupert Leong; Webber Pak Wo Chan
Journal:  Int J Colorectal Dis       Date:  2021-10-26       Impact factor: 2.571

2.  Gall Bladder Disease and the Risk of Small Bowel Cancer-Results from a Nationwide Swedish Cohort Study.

Authors:  Louise Emilsson; Cecilia Radkiewicz; Carol E Semrad; Amit D Joshi; Jonas F Ludvigsson
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

3.  Normal gastrointestinal mucosa at biopsy and subsequent cancer risk: nationwide population-based, sibling-controlled cohort study.

Authors:  Jiangwei Sun; Fang Fang; Ola Olén; Mingyang Song; Jonas Halfvarson; Bjorn Roelstraete; Hamed Khalili; Jonas F Ludvigsson
Journal:  BMC Cancer       Date:  2022-08-13       Impact factor: 4.638

4.  Potential biomarkers and immune characteristics of small bowel adenocarcinoma.

Authors:  Jinggao Feng; Xiayu Tang; Liusong Song; Zhipeng Zhou; Yuan Jiang; Yao Huang
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.